BioLife Solutions (NASDAQ:BLFS) Shares Up 5.4%

BioLife Solutions, Inc. (NASDAQ:BLFS)’s stock price rose 5.4% during mid-day trading on Thursday . The stock traded as high as $16.04 and last traded at $15.96. Approximately 301,339 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 400,998 shares. The stock had previously closed at $15.14.

Analysts Set New Price Targets

Separately, Jefferies Financial Group began coverage on BioLife Solutions in a research note on Thursday, April 4th. They issued a “buy” rating and a $22.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.40.

BioLife Solutions Trading Up 4.8 %

The company has a quick ratio of 1.83, a current ratio of 2.86 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average price of $17.55 and a two-hundred day moving average price of $15.32.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. The company had revenue of $32.73 million for the quarter, compared to the consensus estimate of $32.70 million. BioLife Solutions had a negative return on equity of 13.36% and a negative net margin of 46.37%. On average, equities research analysts anticipate that BioLife Solutions, Inc. will post -0.6 earnings per share for the current year.

Insiders Place Their Bets

In other BioLife Solutions news, SVP Geraint Phillips sold 1,776 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $16.76, for a total transaction of $29,765.76. Following the transaction, the senior vice president now directly owns 58,251 shares in the company, valued at approximately $976,286.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.67, for a total transaction of $156,700.00. Following the sale, the chief marketing officer now owns 129,644 shares of the company’s stock, valued at approximately $2,031,521.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Geraint Phillips sold 1,776 shares of the stock in a transaction on Friday, January 19th. The shares were sold at an average price of $16.76, for a total value of $29,765.76. Following the sale, the senior vice president now directly owns 58,251 shares in the company, valued at approximately $976,286.76. The disclosure for this sale can be found here. Insiders have sold 42,419 shares of company stock worth $706,758 in the last ninety days. 2.70% of the stock is owned by company insiders.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC boosted its position in shares of BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 1,020 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of BioLife Solutions in the 1st quarter worth $36,000. Cubist Systematic Strategies LLC acquired a new stake in shares of BioLife Solutions in the 1st quarter worth $36,000. GAMMA Investing LLC acquired a new stake in shares of BioLife Solutions in the 4th quarter worth $41,000. Finally, US Bancorp DE boosted its position in shares of BioLife Solutions by 374.6% in the 4th quarter. US Bancorp DE now owns 2,520 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 1,989 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.